The Improving HOPE for Alzheimer’s Act
Thanks to our hardworking advocates across the nation, AIM is leading the way to enact laws like the Improving HOPE for Alzheimer's Act, which is improving access to quality health care services for individuals living with Alzheimer's disease.
Signed into law in December 2020, the Improving HOPE for Alzheimer's Act helps people living with dementia and their caregivers by educating clinicians on Alzheimer’s and dementia care planning services available through Medicare. This gives medical providers the knowledge and tools to better help their patients and families living with dementia.
For individuals living with Alzheimer's and their caregivers, care planning is essential to learning about medical and non-medical treatments, clinical trials, and support services available in their community. Accessing these services results in a higher quality of life.
Thanks to our dedicated advocate network, medical providers are now more aware of this resource and individuals living with Alzheimer’s and their caregivers have better access to the care and support they need.
Reach out to our free 24/7 Helpline (800.272.3900) for additional resources to help navigate Alzheimer’s and other dementia.
Be a Champion in the Fight to End Alzheimer’s
Our voices are stronger together. Help AIM advance legislation to improve the lives of people impacted by Alzheimer’s and all other dementia.
- Share your story with elected officials
- Engage on social media
- Write a letter to the editor
Access to Treatment
A restrictive Centers for Medicare & Medicaid Services (CMS) policy that only applies to those living with Alzheimer’s disease is blocking access to FDA-approved treatments. CMS must reverse its unprecedented decision that denies Medicare coverage of current and future treatments for Alzheimer’s.
A National Response to Alzheimer’s and Other Dementia
The bipartisan NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act would build on the progress made over the last decade by continuing to promote rapid research and improve the delivery of clinical care and services for people living with Alzheimer’s.